ATE209927T1 - Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts - Google Patents

Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts

Info

Publication number
ATE209927T1
ATE209927T1 AT94928233T AT94928233T ATE209927T1 AT E209927 T1 ATE209927 T1 AT E209927T1 AT 94928233 T AT94928233 T AT 94928233T AT 94928233 T AT94928233 T AT 94928233T AT E209927 T1 ATE209927 T1 AT E209927T1
Authority
AT
Austria
Prior art keywords
product
mammals
producing
controlling
immune response
Prior art date
Application number
AT94928233T
Other languages
English (en)
Inventor
Anthony M Jevnikar
Shengwu Ma
Calvin R Stiller
Original Assignee
London Health Sciences Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London Health Sciences Ct filed Critical London Health Sciences Ct
Application granted granted Critical
Publication of ATE209927T1 publication Critical patent/ATE209927T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
AT94928233T 1993-09-21 1994-09-21 Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts ATE209927T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939319429A GB9319429D0 (en) 1993-09-21 1993-09-21 Methods and products for controlling immune responses in mammals
PCT/CA1994/000530 WO1995008347A1 (en) 1993-09-21 1994-09-21 Methods and products for controlling immune responses in mammals

Publications (1)

Publication Number Publication Date
ATE209927T1 true ATE209927T1 (de) 2001-12-15

Family

ID=10742259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928233T ATE209927T1 (de) 1993-09-21 1994-09-21 Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts

Country Status (11)

Country Link
US (2) US6338850B1 (de)
EP (1) EP0720484B1 (de)
JP (1) JP3948741B2 (de)
CN (1) CN1135718A (de)
AT (1) ATE209927T1 (de)
AU (1) AU7736794A (de)
CA (1) CA2172398C (de)
DE (1) DE69429353T2 (de)
ES (1) ES2169089T3 (de)
GB (1) GB9319429D0 (de)
WO (1) WO1995008347A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228604B1 (en) 1996-04-10 2001-05-08 Loma Linda University Secreted renilla luciferase
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
BR9915919A (pt) * 1998-10-07 2001-08-21 Syngenta Participations Ag Proteìnas terapeuticamente ativas em plantas
EP2136863A2 (de) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Vorrichtung zur abgabe von arzneimitteln und relevante verbindungen
CN104069567A (zh) * 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) * 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
AU2009312474B2 (en) 2008-11-07 2014-12-04 Insuline Medical Ltd. Device and method for drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (de) 1987-06-24 2002-04-17 Autoimmune, Inc. Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
WO1990001551A1 (en) 1988-07-29 1990-02-22 Washington University School Of Medicine Producing commercially valuable polypeptides with genetically transformed endosperm tissue
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
AU651097B2 (en) 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
HUT69942A (en) 1990-10-15 1995-09-28 Brigham & Womens Hospital Treatment of autoimmun diseases by oral administration of autoantigenes
IL99864A (en) * 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484710A (en) * 1994-01-14 1996-01-16 La Jolla Cancer Research Foundation Method of down-regulating a gene linked to a P-53 responsive element

Also Published As

Publication number Publication date
US20020090371A1 (en) 2002-07-11
CA2172398A1 (en) 1995-03-30
ES2169089T3 (es) 2002-07-01
DE69429353T2 (de) 2002-07-11
EP0720484B1 (de) 2001-12-05
GB9319429D0 (en) 1993-11-03
DE69429353D1 (de) 2002-01-17
WO1995008347A1 (en) 1995-03-30
CN1135718A (zh) 1996-11-13
US6338850B1 (en) 2002-01-15
JPH09507743A (ja) 1997-08-12
CA2172398C (en) 2010-05-04
EP0720484A1 (de) 1996-07-10
AU7736794A (en) 1995-04-10
JP3948741B2 (ja) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE209927T1 (de) Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts
ATA290884A (de) Verfahren zur herstellung eines arzneimittelpraeparates mit kontrollierter und gleichmaessiger freigabe des arzneimittelwirkstoffes
ATE115405T1 (de) Aloe-zusammensetzungen und deren verwendungen.
DE3888274D1 (de) Vorrichtung zur intensiven und kontrollierten Herstellung von Mikroorganismen durch Photosynthese.
DE58907174D1 (de) Verfahren zur Herstellung von flüssigem Roheisen sowie Anlage zur Durchführung des Verfahrens.
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
DE69124276D1 (de) Verfahren zur Herstellung eines mit Sauerstoff angereicherten Produktstroms
ATE202778T1 (de) Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
DE69122828D1 (de) Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort
DE59310300D1 (de) Verfahren und stoffmischung zur herstellung reaktiver schmelzmassen
GB9223332D0 (en) Production of polyhydroxyalkanoate in plants
PL321365A1 (en) Procedures and materials making plants resitant to plant diseases
FI925052A7 (fi) Menetelmä saniteettituotteiden kuten housuvaippojen yhtäjaksoista valm istusta varten ja näin valmistettu saniteettituote
DK0672115T3 (da) Fremgangsmåde til kloningsdyrkning af Streptococcus pneumoniae
ATE14562T1 (de) Pyrogen hergestellte kieselsaeure und verfahren zu ihrer herstellung.
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE58903917D1 (de) Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels sowie daraus hergestelltes arzneimittel und verfahren zu seiner herstellung.
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
ZA90603B (en) Moulded bodies for the nutrition of plant cultures and a process for their preparation
ZA96795B (en) An administration form for the release of collagenase to wounds and a process for its production
DK0530260T3 (da) Fremgangsmåde til fremstilling af et proteinagtigt materiale
HU912163D0 (en) Process for the production of tiazolydine-carbonic acid-derivatives and medical products containing them
DE69122177D1 (de) Verfahren und Apparat zur Herstellung supraleitender Dünnschichten
DE69531554D1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
FI940610L (fi) Menetelmä alfa-glukosidien ja alfa-glukosidiesterien entsymaattiseksi valmistamiseksi sekä näin saatujen tuotteiden käyttö

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties